Recombinant Human FAM217A protein

**Background of FAM217A Recombinant Protein**

FAM217A (Family with sequence similarity 217 member A) is a protein-coding gene whose biological functions remain partially characterized, though emerging studies suggest its involvement in cellular processes such as proliferation, differentiation, and signaling. The gene is evolutionarily conserved, highlighting its potential importance in fundamental biological mechanisms. FAM217A has been linked to several human diseases, including cancers (e.g., glioma, colorectal cancer) and neurodevelopmental disorders, though its precise role in these contexts is under investigation.

Recombinant FAM217A protein is produced through genetic engineering techniques, typically expressed in *E. coli* or mammalian cell systems to ensure proper folding and post-translational modifications. This engineered protein retains the functional domains of the native protein, enabling researchers to study its interactions, structural features, and activity *in vitro* or in cellular models. Its production often involves affinity tags (e.g., His-tag) for purification and detection, ensuring high purity and stability for experimental use.

Current research focuses on elucidating FAM217A's molecular interactions, particularly its potential roles in DNA repair, cell cycle regulation, or as a component of protein complexes. For instance, studies suggest FAM217A may modulate Wnt/β-catenin signaling or act as a tumor suppressor in certain cancers. Its recombinant form is critical for generating antibodies, validating binding partners, and screening for therapeutic targets. Additionally, dysregulation of FAM217A expression in disease models underscores its relevance as a biomarker or drug target.

Despite progress, the full scope of FAM217A's functions remains unclear, necessitating further exploration using recombinant protein tools to unravel its contributions to health and disease.